Last updated: October 11, 2012
Sponsor: Watson Pharmaceuticals
Overall Status: Completed
Phase
4
Condition
Menopause
Treatment
N/AClinical Study ID
NCT00224094
ALO0102
Ages 42-70 Female Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Healthy
Naturally menopausal women
Aged 42-70 years
Currently using combination estrogen-progestin replacement therapy
Exclusion
Exclusion Criteria:
Women with contraindications to HRT use, including:Unexplained vaginal bleeding, liverdisease, breast or endometrial cancer, venous thromboembolic events
Thyroid disease
Adrenal disease
Study Design
Total Participants: 27
Study Start date:
January 01, 2002
Estimated Completion Date:
Connect with a study center
Massachusetts General Hospital
Boston, Massachusetts 02114
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.